Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
PLoS One. 2012;7(6):e39968. doi: 10.1371/journal.pone.0039968. Epub 2012 Jun 26.
Fenretinide (4-HPR) is a synthetic retinoid that exhibits potent antitumor and chemopreventive activities against different malignancies, including ovarian tumors. We previously showed that in ovarian cancer cells, 4-HPR induces apoptosis through a signaling cascade starting from reactive oxygen species (ROS) generation and involving endoplasmic reticulum (ER) stress response, Jun N-terminal Kinase (JNK) activation, and induction of the proapoptotic PLAcental Bone morphogenetic protein (PLAB). Since recent studies have shown that the oncogene ALL1-fused from chromosome 1q (AF1q), a retinoic acid target gene, is implicated in apoptosis induction by several therapeutic agents, we investigated its possible involvement in the apoptosis induced by 4-HPR in ovarian cancer cells.
METHODOLOGY/PRINCIPAL FINDINGS: Protein expression analysis, performed in ovarian cancer cells and extended to other histotypes (breast, neuroblastoma, and cervical), revealed that 4-HPR enhanced AF1q expression in cancer cells sensitive to the retinoid but not in resistant cells. Through gene silencing, AF1q was found functionally involved in 4-HPR-induced apoptosis in A2780, an ovarian cancer cell line highly sensitive to retinoid growth inhibitory and apoptotic effects. Inhibition of the signaling intermediates of the 4-HPR apoptotic cascade showed that AF1q upregulation was depended on prior generation of ROS, induction of ER stress response, JNK activation, and PLAB upmodulation. Finally, we found that direct overexpression of AF1q, in the absence of external stimuli, increased apoptosis in ovarian cancer cell lines.
CONCLUSIONS/SIGNIFICANCE: The study expands the knowledge of the 4-HPR mechanism of action, which has not yet been completely elucidated, identifying AF1q as a novel mediator of retinoid anticancer activity. In addition, we demonstrate, for the first time, that AF1q plays a role in the onset of basal apoptosis in ovarian cancer cells, thus providing new information about the activity of this protein whose biologic functions are mostly unknown.
芬维 A 酯(4-HPR)是一种合成维 A 酸,对包括卵巢肿瘤在内的多种恶性肿瘤具有强大的抗肿瘤和化学预防作用。我们之前的研究表明,在卵巢癌细胞中,4-HPR 通过从活性氧(ROS)产生开始的信号级联诱导细胞凋亡,该信号级联涉及内质网(ER)应激反应、Jun N-末端激酶(JNK)激活和促凋亡 PLAcental 骨形态发生蛋白(PLAB)的诱导。由于最近的研究表明,作为维 A 酸靶基因的染色体 1q 上融合的致癌基因 ALL1(AF1q)参与了几种治疗药物诱导的细胞凋亡,因此我们研究了它在卵巢癌细胞中由 4-HPR 诱导的凋亡中的可能作用。
方法/主要发现:在卵巢癌细胞中进行的蛋白表达分析,并扩展到其他组织类型(乳腺、神经母细胞瘤和宫颈),发现 4-HPR 在对维 A 酸敏感的癌细胞中增强了 AF1q 的表达,但在耐药细胞中则没有。通过基因沉默,AF1q 被发现在 A2780(一种对维 A 酸生长抑制和凋亡作用高度敏感的卵巢癌细胞系)中,在 4-HPR 诱导的凋亡中具有功能作用。抑制 4-HPR 凋亡级联的信号中间体表明,AF1q 的上调依赖于 ROS 的产生、内质网应激反应的诱导、JNK 的激活和 PLAB 的上调。最后,我们发现,在没有外部刺激的情况下,AF1q 的直接过表达增加了卵巢癌细胞系的凋亡。
结论/意义:该研究扩展了 4-HPR 作用机制的知识,该机制尚未完全阐明,确定 AF1q 为新型维 A 酸抗癌活性的调节剂。此外,我们首次证明,AF1q 在卵巢癌细胞的基础凋亡起始中发挥作用,从而提供了有关该蛋白活性的新信息,该蛋白的生物学功能大多未知。